Advaxis Inc represents a commitment to innovation, collaboration, and patient-centricity. As a biotechnology company, Advaxis is driven by a mission to develop groundbreaking immunotherapies for cancer treatment. With a focus on advancing science and technology, they aim to revolutionize the field of oncology. At its core, Advaxis believes in the power of teamwork and partnerships to accelerate the development of effective and personalized therapies. By putting patients at the center of their efforts, they aim to improve the lives of those affected by cancer. Advaxis Inc's dedication to cutting-edge research and patient wellness sets it apart in the biotech industry.

Advaxis Inc is primarily present in the United States.

Advaxis Inc, a leading biotechnology company, has achieved several significant milestones. Notably, they successfully developed AXAL, a groundbreaking immunotherapy platform, which has shown promising results in treating various cancer types. Additionally, Advaxis Inc has entered strategic collaborations with renowned pharmaceutical companies, enabling them to expand their research and development capabilities. Furthermore, the company has attained multiple regulatory milestones, including receiving Fast Track designation from the FDA for certain clinical programs. With a strong focus on innovation and a robust pipeline of potential therapies, Advaxis Inc continues to make significant strides in the field of immunotherapy.

Advaxis Inc is a biotechnology company with a rich history and background. Founded in 2002, Advaxis is focused on developing novel immunotherapies to treat cancer. The company leverages its expertise in Listeria monocytogenes (a type of bacteria) technology to stimulate the immune system and fight cancerous cells. With a commitment to revolutionizing cancer treatment, Advaxis has pioneered advancements in immunotherapy, spearheading clinical trials and collaborations to bring its innovative therapies to patients in need. With its cutting-edge research and dedication to improving patient outcomes, Advaxis Inc has positioned itself as a prominent player in the biotech industry.

The main competitors of Advaxis Inc in the market include companies like Bristol-Myers Squibb, Merck & Co., AstraZeneca, and GlaxoSmithKline. These companies also operate in the field of biotechnology and pharmaceuticals, developing innovative treatments for various diseases and conditions. Advaxis Inc faces competition in terms of research and development, product pipeline, market presence, and intellectual property protection. By closely monitoring advancements and collaborations within the industry, Advaxis Inc can stay ahead of its competitors and continue to deliver cutting-edge solutions in the healthcare sector.

Advaxis Inc is primarily active in the biotechnology industry.

Advaxis Inc operates within the biotechnology industry, focusing on the development and commercialization of immunotherapies designed to treat cancer and infectious diseases. Their business model centers around the development of therapeutic products utilizing their proprietary Lm-based antigen delivery technology platform, known as Lm-Listeria monocytogenes. This platform stimulates the immune system to selectively target and eliminate cancer cells or infected cells. Advaxis Inc collaborates with leading academic institutions, pharmaceutical companies, and research centers to advance their product pipeline. By harnessing the power of the immune system, Advaxis Inc aims to revolutionize the treatment options for patients with a range of cancer types and infectious diseases.

Az Advaxis P/E mutatója -0,02.

Az Advaxis KUV 0.

Az AlleAktien Minőségi Score Advaxis esetében 6/10.

A Advaxis esetében jelenleg nem számítható ki az árbevétel.

A(z) várt Advaxis nyereség -6,77 Mió. USD.

Advaxis, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of novel immunotherapies for the treatment of cancer and infectious diseases. The company is headquartered in Princeton, New Jersey, USA, and operates research and development sites worldwide. Advaxis' business model is based on the development and commercialization of immunotherapies. The company has its own technology platform called Lm-Technology (Listeria monocytogenes), which enables the development of off-the-shelf and patient-specific approaches to cancer and infectious disease treatment. Advaxis' product portfolio includes various immunotherapies, some of which are already being tested in clinical trials. The first approved product is Cervarix®, used for the treatment of advanced cervical cancer in women for whom standard chemotherapy or radiation therapy has failed. Another product currently in clinical trials is ADXS-HOT, an off-the-shelf cancer immunotherapy being developed for various types of cancer by targeting tumor-associated antigens and inducing an immune response. The company has also signed an agreement with another company for the development and commercialization of another potential cancer immunotherapeutic. This therapy combines checkpoint inhibitors and Lm-Technology to suppress cancer cells and stimulate an immune response. As a biopharmaceutical company, Advaxis relies on partnerships and collaborations to successfully bring its products to market and remain competitive. In the past, the company has entered into agreements with large pharmaceutical companies such as Merck, Bristol-Myers Squibb, and AstraZeneca. In addition to its R&D and commercialization activities, Advaxis also enters into partnerships with other companies to license its Lm-Technology platform for other therapeutic purposes. For example, the company has entered into an agreement with GENE.one Life Science Inc. to license the Lm-Technology platform for the development of vaccines against COVID-19 and other infectious diseases. In summary, Advaxis' business model is focused on the development and commercialization of novel immunotherapies for the treatment of cancer and infectious diseases. The company has its own technology platform that allows it to develop off-the-shelf and patient-specific approaches to therapy. Advaxis works closely with other companies to license its technology and form partnerships for the commercialization of its products. With its innovative immunotherapies and promising clinical trials, Advaxis is positioning itself as a significant player in the biotechnology field.

A(z) Advaxis évente alkalommal oszt ki 0 USD összegű osztalékot.

A Advaxis esetében jelenleg nem lehet kiszámítani a osztalékot, vagy a vállalat nem fizet osztalékot.

A(z) Advaxis ISIN kódja: US0076243072.

A Advaxis WKN-je A2PGJ3.

Az Advaxis tőzsdei rövidítése ADXS.

Az elmúlt 12 hónapban a(z) Advaxis osztalékot fizetett összegben. Ez körülbelül osztalékhozamnak felel meg. A következő 12 hóban a(z) Advaxis várhatóan 0 USD összegű osztalékot fog fizetni.

A(z) Advaxis jelenlegi osztalékhozama .

A(z) Advaxis negyedévente fizet osztalékot. Az osztalékokat a következő hónapokban osztják ki: .

A Advaxis az elmúlt 0 évben minden évben fizetett osztalékot.

A következő 12 hónapban 0 USD összegű osztalékra számítanak. Ez 0 % osztalékhozamnak felel meg.

A(z) Advaxis a(z) 'Egészség' szektorhoz van besorolva.

Az utolsó, Advaxis által 2024. 11. 16.-án/én fizetett 0 USD összegű osztalék megszerzéséhez a részvénynek az ex-nap előtti 2024. 11. 16.-nál kellett lennie a portfóliódban.

Az utolsó osztalék kifizetése 2024. 11. 16. időpontban történt.

2023 évben a Advaxis 0 USD összegű osztalékot fizetett ki.

Az Advaxis osztalékait USD fizeti ki.